Pharma Exclusives Pressreleases
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
Saturday, November 15, 2025AbbVieannounced today the launch of Second Winds a new short film that captures the powerful deeply personal journeys of three people living with chronic lymphoma leukemia CLL a common type of blood cancer effecting hundreds
Pfizer Completes Acquisition of Metsera
Friday, November 14, 2025Pfizer Inctoday announced the successful completion of its acquisition of Metsera Inca clinicalstage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases
TrakCel introduces CGT Gateway to revolutionize access to cell & gene therapies for healthcare professionals
Thursday, November 13, 2025TrakCel a leading provider of integrated cell and gene therapy CGT orchestration solutions has today launched CGT Gateway to help Health Care Providers HCPs ease the management of cell and gene therapy products
Galecto Announces Acquisition of Damora Therapeutics
Monday, November 10, 2025Galecto Inc Galecto today announced the completion of the acquisition of Damora Therapeutics Inc Damora a privately held biotechnology company advancing a pipeline of antibody therapeutics aimed at transforming the treatment of mutant calreticulin mu...
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
Friday, November 07, 2025Eli Lilly and Companytoday announced an agreement with the US government to expand access to its obesity medicines and reduce patient costs The agreement builds on Lillys longstanding commitment to finding solutions with policymakers that improve acc...
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma
Tuesday, November 04, 2025Moderna Inc today announced that the first patient has been dosed in a Phase study of mRNA the Companys investigational mRNAbased Tcell engager TCE for participants with relapsed or refractory multiple myeloma
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
Tuesday, November 04, 2025Merckknown as MSD outside of the United States and Canada today announced that the company through a subsidiary Prometheus BioSciences has reached an agreement with Dr Falk Pharma GmbH Falk to discontinue an existing contract concerning codevelopment...
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
Tuesday, November 04, 2025Merck known as MSD outside of the United States and Canada announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences Blackstone for the development
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis’s ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
Friday, October 31, 2025Codexis Inc a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Nitto Denko Avecia Inc a leading contract development and manufacturing organization CDMO specializing
Lantern Pharma to Present AI-Driven Cancer Drug Development & Research Platforms at Inaugural AI for Biology and Medicine Symposium at UNT
Thursday, October 30, 2025Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine AIBM symposium at the University of North Texas
